Shanghai Haohai Biological Technology Co., Ltd.

SEHK:6826 Rapporto sulle azioni

Cap. di mercato: HK$13.7b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Shanghai Haohai Biological Technology Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Shanghai Haohai Biological Technology ha un patrimonio netto totale di CN¥6.1B e un debito totale di CN¥390.2M, che porta il suo rapporto debito/patrimonio netto a 6.4%. Le sue attività totali e le sue passività totali sono rispettivamente CN¥7.2B e CN¥1.1B. L'EBIT di Shanghai Haohai Biological Technology è CN¥407.0M rendendo il suo rapporto di copertura degli interessi -6. Ha liquidità e investimenti a breve termine pari a CN¥2.7B.

Informazioni chiave

6.4%

Rapporto debito/patrimonio netto

CN¥390.21m

Debito

Indice di copertura degli interessi-6x
ContantiCN¥2.73b
Patrimonio nettoCN¥6.12b
Totale passivitàCN¥1.07b
Totale attivitàCN¥7.19b

Aggiornamenti recenti sulla salute finanziaria

Recent updates

We Think Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt With Ease

Jul 25
We Think Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt With Ease

Why We Think Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) CEO Compensation Is Not Excessive At All

May 22
Why We Think Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) CEO Compensation Is Not Excessive At All

Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly

Apr 17
Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly

Are Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Paying Above The Intrinsic Value?

Feb 12
Are Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Paying Above The Intrinsic Value?

Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?

Nov 14
Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?

Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet

Jul 28
Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet

We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt

Mar 09
We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt

These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well

Nov 25
These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well

Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet

Jul 30
Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet

Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Intrinsic Value Is Potentially 96% Above Its Share Price

May 08
Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Intrinsic Value Is Potentially 96% Above Its Share Price

Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?

Apr 19
Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?

Analyst Forecasts Just Became More Bearish On Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)

Mar 04
Analyst Forecasts Just Became More Bearish On Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)

Shanghai Haohai Biological Technology Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Mar 03
Shanghai Haohai Biological Technology Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Is Shanghai Haohai Biological Technology (HKG:6826) A Risky Investment?

Jan 10
Is Shanghai Haohai Biological Technology (HKG:6826) A Risky Investment?

Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly

Oct 08
Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly

Here's Why Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt Responsibly

Jul 07
Here's Why Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt Responsibly

Analysts Have Just Cut Their Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Revenue Estimates By 14%

May 27
Analysts Have Just Cut Their Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Revenue Estimates By 14%

These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well

Apr 04
These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well

Investors Who Bought Shanghai Haohai Biological Technology (HKG:6826) Shares A Year Ago Are Now Up 58%

Mar 16
Investors Who Bought Shanghai Haohai Biological Technology (HKG:6826) Shares A Year Ago Are Now Up 58%

Can Mixed Fundamentals Have A Negative Impact on Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Current Share Price Momentum?

Feb 23
Can Mixed Fundamentals Have A Negative Impact on Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Current Share Price Momentum?

What Type Of Shareholders Own The Most Number of Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Shares?

Feb 05
What Type Of Shareholders Own The Most Number of Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Shares?

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( CN¥3.7B ) di 6826 superano le sue passività a breve termine ( CN¥689.8M ).

Passività a lungo termine: Le attività a breve termine di 6826 ( CN¥3.7B ) superano le sue passività a lungo termine ( CN¥381.0M ).


Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: 6826 ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di 6826 è aumentato da 1% a 6.4% negli ultimi 5 anni.

Copertura del debito: Il debito di 6826 è ben coperto dal flusso di cassa operativo ( 161.6% ).

Copertura degli interessi: 6826 matura più interessi di quanti ne paga, quindi la copertura dei pagamenti degli interessi non è un problema.


Bilancio


Scoprire le aziende sane